| IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates |
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.83 per share a year ago. |
zacks.com |
2025-05-13 22:45:38 |
Czytaj oryginał (ang.) |
| IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release |
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-27 13:06:28 |
Czytaj oryginał (ang.) |
| Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround |
IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-02-05 12:36:12 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-01 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ: IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-28 14:35:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-26 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-24 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-22 13:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-18 14:00:00 |
Czytaj oryginał (ang.) |
| IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerning possible violations of federal securities laws. IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. |
accessnewswire.com |
2025-01-17 13:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS |
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-16 20:15:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences downgraded to Hold from Buy at Stifel |
Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmune and inflammatory disease applications for the downgrade. The strategic pivot will trigger the evaluation of both internal and external/ alternatives and an over 70% workforce reduction, the analyst tells investors in a research note. |
https://thefly.com |
2025-01-09 22:51:26 |
Czytaj oryginał (ang.) |
| IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley |
Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune programs, a 73% workforce reduction and plans to evaluate strategic alternatives, the analyst tells investors in a research note. The firm cites near-term uncertainty related to the future of IGM for the downgrade. |
https://thefly.com |
2025-01-09 22:48:01 |
Czytaj oryginał (ang.) |
| IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital |
BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2, down from $21, following the company's strategic update, which included discontinuation of imvotamab and IGM-2644 in autoimmune diseases. Management noted data from Phase 1b studies evaluating imvotamab in patients with rheumatoid arthritis and systemic lupus erythematosus showed insufficient B cell depletion, the analyst tells investors in a research note. BMO says the update was surprising based on the mechanistic rationale of the TCE-CD20 approach "but speaks to the unpredictability" of T cell mediated approaches in cancer and autoimmune disease. It sees the stock trading at IGM's cash following the update. |
https://thefly.com |
2025-01-09 18:26:12 |
Czytaj oryginał (ang.) |
| IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out |
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results. |
marketwatch.com |
2025-01-09 16:27:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs |
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. |
globenewswire.com |
2025-01-09 15:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates |
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago. |
zacks.com |
2024-11-08 11:00:30 |
Czytaj oryginał (ang.) |
| IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update |
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences to Present at Three Upcoming Investor Conferences |
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay |
IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings. |
marketwatch.com |
2024-10-01 15:41:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO |
On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases. |
benzinga.com |
2024-10-01 15:40:20 |
Czytaj oryginał (ang.) |
| IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases |
The biotechnology company says it will focus only on autoimmune diseases. |
barrons.com |
2024-10-01 12:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Tuesday. |
benzinga.com |
2024-10-01 11:54:07 |
Czytaj oryginał (ang.) |
| IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity |
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – |
globenewswire.com |
2024-09-30 20:01:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? |
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-18 14:37:10 |
Czytaj oryginał (ang.) |
| IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit |
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT. |
globenewswire.com |
2024-09-10 20:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy |
IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-08-22 17:00:46 |
Czytaj oryginał (ang.) |
| IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates |
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $1.43 per share a year ago. |
zacks.com |
2024-08-14 13:00:28 |
Czytaj oryginał (ang.) |
| IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update |
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – |
globenewswire.com |
2024-08-14 11:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock? |
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-07-12 14:36:25 |
Czytaj oryginał (ang.) |
| IGM Biosciences to Present at the Jefferies Healthcare Conference |
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York. |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates |
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.33 per share a year ago. |
zacks.com |
2024-05-08 22:56:13 |
Czytaj oryginał (ang.) |
| IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update |
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. |
globenewswire.com |
2024-05-08 20:10:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference |
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT. |
globenewswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-05-03 15:01:03 |
Czytaj oryginał (ang.) |
| IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock? |
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-04-30 17:00:33 |
Czytaj oryginał (ang.) |